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ABSTRACT. In search of myosin II inhibitors with superior research tool properties, a chemical 
optimization campaign of the blebbistatin scaffold was conducted in this paper. (S)-blebbistatin 
is the best known small-molecule inhibitor of myosin II ATPase activity. Unfortunately, as a 
research tool this compound has several deficiencies: it is photolabile and (photo)toxic, has low 
water solubility, and its (fluorescent) precipitates interfere in (fluorescence) readouts. In view of 
obtaining tool compounds with improved properties, both enantiomers of a series of D-ring 
modified polar analogs were prepared. We identified (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-
aminoblebbistatin (S)-3 as two myosin II inhibitors with a 30-fold higher water solubility than 
(S)-blebbistatin. These molecules furthermore do not cause interference in (fluorescence) 
readouts. (S)-2 and (S)-3 thus are superior alternatives to (S)-blebbistatin as research tools to 
study myosin II.  
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INTRODUCTION 
Myosins are actin-based ATP-driven molecular motor proteins.
1
 They play a key role in many 
forms of eukaryotic motility, such as muscle contraction, cytokinesis, intracellular trafficking, 
phagocytosis, and cell movement.
2-4
 (S)-blebbistatin (S)-1 (Figure 1) is a micromolar, cell-
permeable ATPase cycle inhibitor of myosin II. Its main virtue is specificity: it does not 
modulate myosins I, V, and X.
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Figure 1. Overview of the state of the art and present work. 
 
 
Since its discovery in 2001,
6
 (S)-blebbistatin (S)-1 has rapidly been embraced as a research 
tool: it has played a significant role in the understanding of the function of myosin II in 
biological processes,
2-4
 and has provided insight into the cellular and molecular events that drive 
a range of myosin II-related diseases, such as invasion in malignant disease,
7-10
 viral 
infections,
11-13
 bacterial infections,
14
 glaucoma,
15
 progressive renal disease,
16
 and 
methamphetamine use relapse.
17
 However, as is the case for other ‘first-in-class’ tool 
compounds, (S)-blebbistatin (S)-1 bears deficiencies that encumber or prohibit its use in 
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sophisticated model systems: it is photolabile,
18-23
 (photo)toxic,
18,21,22
 has limited water 
solubility,
23-25
 and its (fluorescent) precipitates interfere in (fluorescence) readouts.
26-28
 The main 
objective in the present study was therefore to develop (S)-blebbistatin analogs with superior 
research tool characteristics. We hypothesized that this would require the introduction of polar 
functionalities on its scaffold (Figure 1): the ensuing increased aqueous solubility would 
eliminate assay readout issues by preventing the formation of precipitates. 
 
Following this rationale, the novel analogs (S)-3’-hydroxyblebbistatin (S)-2, (S)-3’-
aminoblebbistatin (S)-3, (S)-3’-cyanoblebbistatin (S)-13, (S)-3’-carbamoylblebbistatin (S)-16, 
and (S)-3’-carboxyblebbistatin (S)-17, and their R-enantiomers (negative controls),29 were 
synthesized. The myosin II inhibitory activity of these compounds was evaluated in a 
biochemical assay (i.e. an ATPase assay). We furthermore discuss the physicochemical 
properties of these molecules, including solubility and fluorescence data. During the final 
preparation of this manuscript, a paper on a single polar blebbistatin derivative with improved 
physicochemical properties was published by Varkúti et al.
30
 Our study provides broader context 
by the exploration of an elaborate family of polar analogs. We furthermore provide detailed 
synthetic protocols and analytical data, in order to facilitate the broad use of our molecules as 
research tool compounds to study myosin II. 
 
RESULTS AND DISCUSSION 
1. Chemistry 
Polar blebbistatin analogs (S)- and (R)-2,3,13,16,17 were prepared after select adaptation of a 
route that has proven successful for (S)-blebbistatin (S)-1.
20
 The syntheses commenced with 
arylations of 2-pyrrolidinone (5) in very good yields (Scheme 1).  
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Scheme 1. Synthesis of quinolones 9a–d. Reagents and conditions: (a) CuI, 5, tris(3,5-dimethyl-
1H-pyrazol-1-yl)methane, K3PO4, 1,4-dioxane, reflux, 24–72 h; (b) 1) POCl3, CH2Cl2, rt, 24 h, 
2) 7, CH2Cl2, 35 °C, 24 h; (c) LiHMDS, THF, 0 °C, 1 h. 
 
 
The synthesis of amidine 8a, starting from pyrrolidinone 6a and amine 7, was performed in the 
presence of phosphorus oxychloride via a modified procedure of Lucas-Lopez et al.
20
 The 
amount of phosphorus oxychloride was doubled and the reaction time for the formation of the 
chloroiminium intermediate was increased from 3 h to 24 h. In this way, a conversion of 95% 
was obtained (Table 1). Isolation of the amidine out of the crude reaction mixture via acid-base 
extraction, as reported in the procedure of Lucas-Lopez et al.,
20
 proved difficult and afforded 
amidine 8a in 2% yield. This compound was isolated in 78% yield when the same crude reaction 
mixture was purified by reversed phase automated flash chromatography. This procedure affords 
amidine 8a was obtained in a much higher yield than the previously reported strategies. With 
these conditions in hand, amidines 8b–d were synthesized in the same manner (Scheme 1). The 
presence of (mild) electron withdrawing groups (e.g. protonated amino group (formed under the 
acidic conditions used) in 6c, cyano group in 6d) in pyrrolidinones 6c–d hampered the 
nucleophilic character of the aryl amide, leading to rather high amounts of unreacted starting 
material. A similar observation was made for the electron donating allyloxy group in 6b. 
Attempts to improve this transformation, using alternative reagents or starting materials, and/or 
by the addition of base, were unsuccessful (Table 1).  
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Table 1. Optimization of the synthesis of amidines 8a–d.  
 
Amidine Starting 
material 
Reaction conditions Conversion[a] 
(%) 
Yield 
(%) 
8a 6a 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
95 2[b,c] 
8a 6a 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
95 78[b,d] 
8b 6b 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
62[e] 50[d] 
8c 6c 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
53[e] 29[d,f] 
8d 6d 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
37[e] 30[d] 
8d 6d 
1) 2 equiv Et3N, 1.2 equiv Mukaiyama’s reagent, CH2Cl2, 5 min, rt 
2) 1.2 equiv 7, CH2Cl2, 45 h, r.t. 
0 – [g] 
8d 10
[h] 
1) 2 equiv Et3N, 1.2 equiv Mukaiyama’s reagent, CH2Cl2, 5 min, rt 
2) 1.2 equiv 7, CH2Cl2, 24 h, 35 °C 
13 – [g] 
8d 10
[h] 
1) 2 equiv Et3N, 2 equiv Mukaiyama’s reagent, CH2Cl2, 5 min, rt 
2) 1.2 equiv 7, CH2Cl2, 24 h, 35 °C 
25 – [g] 
8d 10
[h] 
1) 2 equiv Et3N, 2 equiv POCl3, CH2Cl2, 5 min, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
3 – [g] 
8d 10
[h] 
1) 2 equiv Et3N, 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
3 – [g] 
8d 10
[h] 
1) 2 equiv POCl3, CH2Cl2, 5 min, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
14 – [g] 
8d 10
[h] 
1) 2 equiv POCl3, CH2Cl2, 24 h, rt 
2) 1.05 equiv 7, CH2Cl2, 24 h, 35 °C 
15 – [g] 
[a] 
1
H NMR. [b] Previously prepared by Lucas-Lopez et al. in 41% yield: 1) 1.1 equiv 6a, 
1 equiv POCl3, CH2Cl2, 3 h, rt; 2) 1 equiv 7, CH2Cl2, 16 h, 35 °C.
20
 [c] Purified via acid-base 
extraction. [d] Purified via reversed phase automated flash chromatography. [e] Unreacted 
starting material was fully recovered. [f] 85% purity. [g] Not isolated. [h] Pyrrolidinethione 10 
was prepared from pyrrolidinone 6d and Lawesson’s reagent.31 When excess Lawesson’s reagent 
(more than 0.5 equivalents) and/or prolonged reaction times (more than 30 minutes) were used at 
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elevated temperatures (70 °C), thionation of the nitrile functionality in pyrrolidinethione 10 also 
occurred.  
 
 
Intramolecular cyclization gave quinolones 9a–d in good to excellent yields (Scheme 1). The 
ensuing asymmetric α-hydroxylation (Scheme 2) was carried out using Davis’ oxaziridine 
methodology. In all cases, quinolones 9a–d were completely converted to α-hydroxy ketones 
(S)- and (R)-1,11–13, but isolated yields varied. A single recrystallization from CH3CN or EtOH 
resulted in highly optically enriched (S)- and (R)-1,11 and (S)- and (R)-12, respectively. 
Intermediates 11 and 12 were deprotected in high yields (Scheme 3) without affecting the 
blebbistatin scaffold. Nitriles (S)- and (R)-13 were selectively hydrolyzed to amides (S)- and (R)-
16, which were successfully optically enriched by recrystallization from EtOH. Amides (S)- and 
(R)-16 were further converted into carboxylic acids (S)- and (R)-17. Isolation of these acids from 
the crude reaction mixture proved tedious, due to their polar and zwitterionic nature. (S)-17 was 
only recovered in low yield by preparative TLC. Conversely, a quick work-up of the crude 
mixture afforded (R)-17 in good yield and similar purity as obtained for (S)-17 after preparative 
TLC. Finally, the absolute configuration of (S)-2 and (R)-2 was determined by X-ray analysis 
(see the Supporting Information), and this confirms the formation of (S)- and (R)-α-hydroxy 
ketones using Davis’ oxaziridines 14 and 15, respectively (Scheme 2).  
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Scheme 2. Asymmetric α-hydroxylation of quinolones 9a–d. Reagents and conditions: 1) 
LiHMDS, THF, −78 °C, 30 min, 2) 14 (for (S)-1,11–13) or 15 (for (R)-1,11–13), THF, −15 °C, 
16 h. [a] Determination of ee via chiral HPLC analysis. [b] After recrystallization from CH3CN. 
[c] After recrystallization from EtOH. 
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Scheme 3. Deprotection of (S)- and (R)-11–13: formation of polar blebbistatin analogs (S)- and 
(R)-2,3,16,17. Reagents and conditions: (a) Pd(PPh3)4, K2CO3, MeOH, 50 °C, 1 h; (b) N,N’-
dimethylbarbituric acid, Pd(PPh3)4, CH2Cl2, reflux, 1 h; (c) Et2NOH, CH2Cl2, reflux, 48 h; (d) 
H2SO4, H2O, 70 °C, 14 h. [a] Determination of ee via chiral HPLC analysis. [b] After 
recrystallization from EtOH. [c] Determination of ee via chiral HPLC analysis of corresponding 
methyl ester. 
 
 
The key steps in the synthesis of blebbistatin derivatives 2, 3, 13, 16 and 17 were the 
successful introduction and removal of a suitable masked polar group. Of the evaluated 
alternatives (OMEM, OAlloc, OAllyl, NHMEM, NHAlloc, N(Allyl)2, CN), only the allyl 
protecting group and cyano function proved appropriate for the preparation of blebbistatin 
analogs 2,3 and 13,16,17, respectively. Finally, enantiopurity of both enantiomers of all newly 
synthesized blebbistatin derivatives 2,3,11–13,16,17 was determined via chiral HPLC analysis. 
Unfortunately, this feature is often neglected in literature.
24,30
 Knowledge of the enantiopurity of 
(S)-blebbistatin or its derivatives is highly important when using these molecules to modulate 
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myosin II function in biochemical or biological experiments, as the (R)-enantiomers display no 
affinity for myosin II (vide infra). 
 
2. Biochemical evaluation 
The myosin II inhibitory properties of both enantiomers of compounds 1–3, 13, 16 and 17 
were evaluated in vitro in a steady state ATPase assay using rabbit skeletal muscle myosin II. 
The half-maximum inhibitory concentrations (IC50) of (S)-3’-hydroxyblebbistatin (S)-2 and (S)-
3’-aminoblebbistatin (S)-3 in the ATPase assay (Figure 2, Table 2) lie somewhat higher, but still 
in the same order of magnitude as that of parent compound (S)-1. (S)-3’-cyanoblebbistatin (S)-13 
proved less potent. The maximal extent of inhibition is the same for all four compounds at high 
concentrations (50–100 µM). (S)-3’-carbamoylblebbistatin (S)-16 and (S)-3’-carboxyblebbistatin 
(S)-17, on the other hand, were ineffective at concentrations up to 100 µM. As expected,
29
 all 
(R)-enantiomers lacked efficacy. 
The data generated from the ATPase assay yield useful SAR information. They highlight that 
the (S)-configuration is essential for activity, confirming a similar binding mode for (S)-3’-
hydroxyblebbistatin (S)-2, (S)-3’-aminoblebbistatin (S)-3 and (S)-3’-cyanoblebbistatin (S)-13 as 
for (S)-1. The data also reveal that small hydrophilic groups in the meta-position of ring D can be 
accommodated, but do not influence potency in an appreciable manner. Large polar groups are 
not well tolerated. The kinetics of the chemo-mechanical cycle of myosin may play an important 
role in the observed ligand discrimination. Preliminary in silico studies (data not shown) suggest 
that steric and temporal restrictions imposed by the path(s) leading toward the binding site may 
be a possible reason behind this observation. A full report of these investigations will be 
disclosed in due course. 
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Figure 2. Biochemical evaluation of the myosin II inhibitory properties of both enantiomers of 
compounds 1–3, 13, 16 and 17, evaluated in an ATPase assay with rabbit skeletal muscle myosin 
II. Examples of dose-response curves and 4-parameter logistic curve fitting obtained for (A) (S)-
blebbistatin (S)-1 and (R)-blebbistatin (R)-1, (B) (S)-3’-hydroxyblebbistatin (S)-2 and (R)-3’-
hydroxyblebbistatin (R)-2, (C) (S)-3’-aminoblebbistatin (S)-3 and (R)-3’-aminoblebbistatin (R)-
3, (D) (S)-3’-cyanoblebbistatin (S)-13 and (R)-3’-cyanoblebbistatin (R)-13, (E) (S)-3’-
carbamoylblebbistatin (S)-16 and (R)-3’-carbamoylblebbistatin (R)-16, and (F) (S)-3’-
carboxyblebbistatin (S)-17 and (R)-3’-carboxyblebbistatin (R)-17. Data points represent the 
means ± s.d. of at least three samples (N = 1). Concentrations higher than 40 µM caused (S)-3’-
cyanoblebbistatin (S)-13 to precipitate in the assay buffer (Figure S72 in the Supporting 
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Information), so the relative ATPase activity of (S)-blebbistatin (S)-1 at a concentration of 
32.5 µM was used to set the lower asymptote of the fitted curve. 
 
 
Table 2. Biochemical and physicochemical evaluation of compounds (S)- and (R)-1–3, 13, 16, 
and 17: half-maximum inhibitory concentrations (IC50) for the steady state ATPase activity of 
rabbit skeletal muscle myosin II, and solubility data in PBS pH 7.4 buffer. 
Compound IC50
[a] 
(µM) 
Solubility[b] 
(µM) 
Compound IC50
[a] 
(µM) 
(S)-1 2.16 ± 0.14 6.18 ± 0.08 (R)-1 >100[c] 
(S)-2 19.3 ± 0.5 193 ± 1 (R)-2 >300[d] 
(S)-3 14.1 ± 0.1 186 ± 9 (R)-3 >300[d] 
(S)-13 48.5 ± 0.1 N.D.[e] (R)-13 >40[f] 
(S)-16 >100[c] 86.3 ± 6.7 (R)-16 >100[c] 
(S)-17 >100[c] >200[g] (R)-17 >100[c] 
[a] Data represent mean ± s.d. of two independent experiments (1.6% DMSO). [b] Data represent 
mean ± s.d. of two independent experiments (2% DMSO). [c,d,f,g] Highest compound 
concentrations used were 100, 300, 40, and 200 µM, respectively. [e] Not determined. [f] 
Concentrations >40 µM resulted in compound precipitation in the assay buffer (Figure S73 in the 
Supporting Information). 
 
 
 
3. Physicochemical evaluation 
A major issue with (S)-blebbistatin (S)-1 is its limited solubility in aqueous media. Since high 
(S)-1 concentrations (50–100 µM) are typically required to halt myosin II dependent cellular 
processes, experiments are de facto carried out in oversaturated solutions.
5
 This creates 
uncertainty about actual assay concentrations and, as will be shown below, can produce 
interfering precipitates. We found that the solubility of (S)-blebbistatin (S)-1 in PBS pH 7.4 
buffer (Table 2) is 6.18 ± 0.08 µM at 2% (v/v) DMSO. As anticipated, the solubility of the newly 
synthesized alcohol, amine, amide and carboxylic acid derivatives under the same conditions 
proved significantly higher. (S)-3’-cyanoblebbistatin (S)-13 was not evaluated, since 
precipitation was noted above 40 µM in the ATPase assay. Most importantly, the solubility of 
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the most potent derivatives, (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-aminoblebbistatin (S)-3, 
is over 30 times higher than that of (S)-blebbistatin (S)-1. 
A second, even more severe limitation of (S)-blebbistatin (S)-1 is its interference when using 
fluorescence as a readout. Two of the most important experiments in this context are cardiac 
optical mapping,
26,32 
and the study of myosin II function in the cell. Both are routinely conducted 
using (S)-blebbistatin (S)-1 as a tool to inhibit myosin II. In the former experiment, calcium 
concentrations are measured using fluorescent Ca
2+
 indicators (Fluo-3, Fluo-4, Fluo-5F). When 
studying myosin II function in the cell, fluorescence microscopy with GFP-labeled myosin II is 
often used. In both experimental setups, the use of (S)-blebbistatin (S)-1 is accompanied with 
fluorescence interference upon excitation in the 488 nm region. It is often assumed that (S)-
blebbistatin (S)-1 solutions are highly fluorescent and thereby cause this interference.
20,23
 
However, during our own prior biological work in media containing high (S)-blebbistatin (S)-1 
concentrations, we had realized that (S)-blebbistatin (S)-1 crystals, rather than (S)-blebbistatin 
(S)-1 in solution, were the actual cause of the observed interference. We therefore hypothesized 
that the use of more water soluble blebbistatin analogs would eliminate fluorescence 
interference. To test this assumption, we exposed MCF-7/6 breast carcinoma cells, a commonly 
used cell line in our laboratories,
7
 to low and high concentrations of (S)-blebbistatin (S)-1 and 
imaged after 24 h of incubation (Figure 3). At low (S)-blebbistatin (S)-1 concentrations (Figures 
3A and 3B), no fluorescence upon 488 nm excitation was observed. Conversely, at high (S)-
blebbistatin (S)-1 concentrations (Figures 3C and 3D), fluorescent precipitates were clearly 
visible. When repeating the experiment with the most potent polar derivatives, (S)-3’-
hydroxyblebbistatin (S)-2 (Figure S75 in the Supporting Information) and (S)-3’-
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aminoblebbistatin (S)-3 (Figures 3E and 3F, and Figure S74 in the Supporting Information), no 
fluorescence was detected. 
 
Figure 3. Low solubility of (S)-blebbistatin (S)-1 results in precipitates that interfere during 
fluorescence imaging when applied at high concentrations. Fluorescence imaging of MCF-7/6 
breast carcinoma cells treated with (S)-blebbistatin (S)-1 and (S)-3’-aminoblebbistatin (S)-3. (A) 
Brightfield and (B) fluorescence image (488 nm excitation) of treatment with 5 µM (S)-
blebbistatin (S)-1. (C) Brightfield and (D) fluorescence image (488 nm excitation) of treatment 
with 50 µM (S)-blebbistatin (S)-1. (E) Brightfield and (F) fluorescence image (488 nm 
excitation) of treatment with 50 µM (S)-3’-aminoblebbistatin (S)-3. Exposure time in B, D, and F 
is equal. Scale bar, 50 µm. 
 
 
As (S)-blebbistatin (S)-1, (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-aminoblebbistatin (S)-3 
show similar, weak, fluorescence upon 488 nm excitation (Figure 4), these observations confirm 
that the described fluorescence issues of (S)-blebbistatin (S)-1 are due to its low aqueous 
solubility and the resulting formation of precipitates. (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-
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aminoblebbistatin (S)-3 are therefore superior tools for cardiac optical mapping and myosin II 
studies. 
 
 
Figure 4. Fluorescent properties of (S)-blebbistatin (S)-1, (S)-3’-hydroxyblebbistatin (S)-2 and 
(S)-3’-aminoblebbistatin (S)-3. Emission spectra upon excitation at a wavelength of (A) 488 nm 
and (B) 365 nm. 
 
 
CONCLUSIONS 
Both enantiomers of a series of polar blebbistatin analogs (2, 3, 13, 16 and 17) were 
synthesized in search of myosin II inhibitors with enhanced physicochemical properties and 
superior research tool characteristics as compared to (S)-blebbistatin (S)-1. The most important 
steps in their preparation consisted of (i) introduction of a suitable masked polar group in the 
beginning of the sequence (i.e. an allyl protecting group and cyano function for 2,3 and 13,16,17, 
16 
 
respectively), (ii) an optimized synthesis and purification of the amidine intermediates and (iii) 
removal of the protecting group at the end of the pathway without affecting the blebbistatin 
scaffold. The enantiopurity of both enantiomers of these newly synthesized blebbistatin 
derivatives was confirmed. All (R)-enantiomers lacked myosin II inhibitory properties. This 
highlights the importance of a correct assessment of the enantiopurity of (S)-blebbistatin 
(derivatives) in terms of their use as myosin II inhibitors. Our biochemical and physicochemical 
evaluation demonstrated that both (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-aminoblebbistatin 
(S)-3 combine good myosin II inhibitory properties with a 30 times higher aqueous solubility 
than (S)-blebbistatin (S)-1. These polar analogs moreover do not show interference in 
fluorescence readouts. Given these virtues, (S)-3’-hydroxyblebbistatin (S)-2 and (S)-3’-
aminoblebbistatin (S)-3 can be considered superior research tool molecules for the study of 
myosin II.  
 
MATERIALS AND METHODS 
1. Chemistry 
The synthesis of compounds 1–3, 11–13, 16 and 17 is provided below. The purity of all final 
compounds was 95% or higher, as determined by LC-MS analysis. The synthesis of compounds 
9a–d is detailed in the Supporting Information. 
1.1. General 
Dichloromethane was dried by heating under reflux over CaH2 and distilled under an 
atmosphere of nitrogen. Tetrahydrofuran was dried by heating under reflux with 
sodium/benzophenone under a nitrogen atmosphere and collected by distillation. Dry 
1,4-dioxane and dry methanol were purchased from Sigma-Aldrich and Acros Organics, 
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respectively. Reagents were purchased at the highest commercial quality and were used as 
received without further purification. 
Yields refer to chromatographically and spectroscopically (
1
H NMR) homogeneous material, 
unless otherwise stated. 
Reactions were monitored on an Agilent 1200 series HPLC system fitted with an Ascentis® 
Express C18-column (2.7 µm particle size, 4.6 mm internal diameter), using acetonitrile/water 
(5 mM NH4OAc) as eluent. Low-resolution mass spectra were recorded on an Agilent 1100 
series VL mass spectrometer (ESI, 70 eV). High-resolution mass spectra (HRMS) were recorded 
using an Agilent Technologies 6210 series time-of-flight (TOF) mass spectrometer equipped 
with an ESI/APCI-multimode source. Thin layer chromatography (TLC) was carried out on 
0.25 mm Merck silica plates (60 F254) and spots were visualized by UV light (254 nm). Flash 
column chromatography was performed on an automated Reveleris® X2 flash chromatography 
system, using Reveleris® C18 or Reveleris® silica cartridges. Melting points were determined 
using a Wagner & Munz WME Heizbank Kofler bench. 
NMR spectra were recorded on a Bruker Avance III instrument. 
1
H NMR (400 MHz) chemical 
shifts are recorded in CDCl3 or DMSO-d6, reported in ppm and measured relative to 
tetramethylsilane or the residual undeuterated solvent as the internal reference, respectively. 
13
C NMR (100.6 MHz) chemical shifts are reported in ppm and were measured relative to the 
residual undeuterated solvent as the internal reference. The following abbreviations were used to 
explain NMR peak multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = 
multiplet, br = broad. 
The enantiomeric excess (ee) of chiral compounds was determined via chiral HPLC analysis 
using a Daicel Chiralpak IA column (5 µm particle size, 150 mm length, 2.1 mm internal 
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diameter). Detection wavelengths were set at 268, 234 and 296 nm. Analyses under reversed 
phase and normal phase conditions were performed at 25 °C and 35 °C, respectively. Optical 
rotations were obtained on a Jasco P-2000 polarimeter and are reported in deg mL g
-1
 dm
-1
; 
concentrations are reported in grams per 100 mL. 
1.2. General procedure for the asymmetric α-hydroxylation of quinolones 
The asymmetric α-hydroxylation of quinolones 9a,b,d was adopted from Lucas-Lopez et al.20 
An oven-dried bulb of 50 mL, evacuated and back-filled with argon (5×), was loaded with 
5 mL of dry tetrahydrofuran and quinolone (1.00 mmol, 1 equiv). Then, the solution was cooled 
to −78 °C and 1.20 mL of lithiumbis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 
1.20 mmol, 1.2 equiv) was added. The reaction was stirred for 30 minutes at −78 °C and a 
solution of Davis’ oxaziridine 14 or 15 (0.716 g, 2.40 mmol, 2.4 equiv) in dry tetrahydrofuran 
(10 mL) was added via syringe. Subsequently, the mixture was stirred at −15 °C for 16 hours 
before being quenched by the addition of 35 mL of saturated aqueous NH4Cl. Saturated aqueous 
Na2S2O3 (100 mL) was then added and the reaction mixture was extracted with diethyl ether 
(3× 150 mL). The combined organic extracts were concentrated in vacuo. The residue was 
dissolved in 40 mL of dichloromethane and subsequently washed with 0.3 M aqueous HCl 
(3× 60 mL). The combined aqueous layers were washed with 60 mL of diethyl ether, basified 
with 3 M aqueous NaOH until pH 10 was reached, and extracted with ethyl acetate (2× 250 mL). 
The combined organic extracts were dried over magnesium sulfate and evaporated in vacuo. 
1.2.1. (S)-3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one 
((S)-1)
20 
(S)-blebbistatin (S)-1 was synthesized from quinolone 9a (0.276 g, 1.00 mmol, 1 equiv) using 
Davis’ oxaziridine 14 (0.716 g, 2.40 mmol, 2.4 equiv). Evaporation in vacuo gave (S)-1 (0.250 g, 
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85%) as bright yellow powder. The enantiomeric excess was 75% as determined by chiral HPLC 
analysis. This powder was redissolved  in 10 mL of boiling acetonitrile and left untouched 
overnight at room temperature, which afforded (S)-blebbistatin (S)-1 (0.108 g, 37%) as bright 
yellow crystals with an enantiomeric excess of >99%. Chiral HPLC: tR ((S)-1) = 7.32 min, 
tR ((R)-1) = 9.77 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 
25 °C). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.23–2.30 (m, 2H), 2.31 (br. s, 3H), 3.90–4.02 (m, 
1H), 4.02–4.12 (m, 1H), 6.84 (s, 1H), 7.13 (d, J = 8.1 Hz, 1H), 7.15 (t, J = 7.3 Hz, 1H), 7.38 (dd, 
J = 8.1, 1.8 Hz, 1H), 7.40–7.47 (m, 2H), 7.54 (d, J = 1.8 Hz, 1H), 8.09 (d, J = 7.9 Hz, 2H). 
1
H NMR spectrum and chiral HPLC chromatograms are provided in Figures S29 and S48–S49, 
respectively, in the Supporting Information. 
1.2.2. (R)-3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one 
((R)-1) 
(R)-blebbistatin (R)-1 was synthesized from quinolone 9a (0.138 g, 0.500 mmol, 1 equiv) 
using Davis’ oxaziridine 15 (0.358 g, 1.20 mmol, 2.4 equiv). Evaporation in vacuo resulted in 
(R)-1 (0.0918 g, 63%) as a yellow powder. The enantiomeric excess was 75% as determined by 
chiral HPLC analysis. The powder was redissolved in 5 mL of boiling acetonitrile and left 
untouched overnight at room temperature, which resulted in (R)-blebbistatin (R)-1 (0.0299 g, 
20%) as bright yellow crystals with an enantiomeric excess of 99%. Chiral HPLC: 
tR ((R)-1) = 9.77 min, tR ((S)-1) = 7.31 min (Daicel Chiralpak IA column, acetonitrile/water 
(50:50), 1.0 mL min
-1
, 25 °C). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.23–2.30 (m, 2H), 2.31 
(br. s, 3H), 3.90–4.02 (m, 1H), 4.02–4.12 (m, 1H), 6.84 (s, 1H), 7.13 (d, J = 8.1 Hz, 1H), 7.15 (t, 
J = 7.3 Hz, 1H), 7.38 (dd, J = 8.1, 1.8 Hz, 1H), 7.40–7.47 (m, 2H), 7.54 (d, J = 1.8 Hz, 1H), 8.09 
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(d, J = 7.9 Hz, 2H). MW = 292.33. Chiral HPLC chromatogram is provided in Figure S50 in the 
Supporting Information. 
1.2.3. (S)-1-(3-(allyloxy)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-11) 
(S)-3’-allyloxyblebbistatin (S)-11 was synthesized from quinolone 9b (11.5 g, 34.6 mmol, 
1 equiv) using Davis’ oxaziridine 14 (24.8 g, 83.0 mmol, 2.4 equiv). Evaporation in vacuo 
resulted in (S)-11 (8.19 g, 68 %) as an orange powder. The enantiomeric excess was 78% as 
determined by chiral HPLC analysis. The powder was redissolved in 80 mL of boiling 
acetonitrile and left untouched for 30 minutes at room temperature. After 20 minutes crystals had 
formed. After an additional 10 minutes, the obtained crystals were filtered off. This resulted in 
(S)-3’-allyloxyblebbistatin (S)-11 (2.29 g, 19%) as bright, gold leaf-like crystals with an 
enantiomeric excess of >99%. mp 176 °C. Chiral HPLC: tR ((S)-11) = 11.2 min, tR ((R)-
11) = 14.2 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 25 °C). 
[α]25D = −327 ± 2 (c = 0.11 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.22–2.29 
(m, 2H), 2.31 (s, 3H), 3.92–4.00 (m, 1H), 4.00–4.09 (m, 1H), 4.62 (dt, J = 5.2, 1.5 Hz, 2H), 5.29 
(dq, J = 10.6, 1.5 Hz, 1H), 5.44 (dq, J = 17.3, 1.5 Hz, 1H), 6.09 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 
6.75 (dd, J = 8.2, 2.0 Hz, 1H), 6.83 (s, 1H), 7.14 (d, J = 8.1 Hz, 1H), 7.32 (t, J = 8.2 Hz, 1H), 
7.39 (dd,  J = 8.1, 1.8 Hz, 1H), 7.50 (dd, J = 8.2, 2.0 Hz, 1H), 7.54 (d, J = 1.8 Hz, 1H), 7.99 (t, 
J = 2.0 Hz, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.7, 48.0, 68.7, 73.4, 106.9, 
110.3, 112.2, 118.0, 121.5, 126.4, 126.8, 129.9, 132.9, 134.2, 137.0, 142.2, 149.4, 158.8, 165.8, 
195.0. MS (ESI): m/z (%) = 348.6 ([M+H]
+
, 100). HRMS (ESI): calculated for C21H21N2O3 
([M+H]
+
) 349.1547; found 349.1544. MW = 348.40. 
1
H NMR spectrum, 
13
C NMR spectrum and 
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chiral HPLC chromatograms are provided in Figures S30–S31 and Figures S51–S52 in the 
Supporting Information. 
1.2.4. (R)-1-(3-(allyloxy)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((R)-11) 
(R)-3’-allyloxyblebbistatin (R)-11 was synthesized from quinolone 9b (2.66 g, 8.00 mmol, 
1 equiv) using Davis’ oxaziridine 15 (5.73 g, 19.2 mmol, 2.4 equiv). Evaporation in vacuo 
resulted in (R)-11 (2.15 g, 77%) as an orange powder. The enantiomeric excess was 79% as 
determined by chiral HPLC analysis. The powder was redissolved in 20 mL of boiling 
acetonitrile and left untouched for 30 minutes at room temperature. After 20 minutes crystals had 
formed, which were filtered off after an additional 10 minutes. This resulted in (R)-3’-
allyloxyblebbistatin (R)-11 (1.00 g, 36%) as bright, gold leaf-like crystals with an enantiomeric 
excess of >99%. mp 170 °C. Chiral HPLC: tR ((R)-11) = 14.2 min, tR ((S)-11) = 11.2 min (Daicel 
Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 25 °C). [α]25D = +313 ± 3 
(c = 0.12 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.22–2.29 (m, 2H), 2.31 (s, 
3H), 3.92–4.00 (m, 1H), 4.00–4.09 (m, 1H), 4.62 (dt, J = 5.2, 1.5 Hz, 2H), 5.29 (dq, J = 10.6, 
1.5 Hz, 1H), 5.44 (dq, J = 17.3, 1.5 Hz, 1H), 6.09 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.75 (dd, 
J = 8.2, 2.0 Hz, 1H), 6.83 (s, 1H), 7.14 (d, J = 8.1 Hz, 1H), 7.32 (t, J = 8.2 Hz, 1H), 7.39 (dd,  
J = 8.1, 1.8 Hz, 1H), 7.50 (dd, J = 8.2, 2.0 Hz, 1H), 7.54 (d, J = 1.8 Hz, 1H), 7.99 (t, J = 2.0 Hz, 
1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.7, 48.0, 68.7, 73.4, 106.9, 110.3, 112.2, 
118.0, 121.5, 126.4, 126.8, 129.9, 132.9, 134.2, 137.0, 142.2, 149.4, 158.8, 165.8, 195.0. MS 
(ESI): m/z (%) = 348.6 ([M+H]
+
, 100). HRMS (ESI): calculated for C21H21N2O3 ([M+H]
+
) 
349.1547; found 349.1551. MW = 348.40. Chiral HPLC chromatogram is provided in 
Figure S53 in the Supporting Information. 
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1.2.5. (S)-1-(3-(diallylamino)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4 one ((S)-12) 
(S)-3’-diallylaminoblebbistatin (S)-12 was synthesized from the crude quinolone 9c (3.96 g, 
10.7 mmol, 1 equiv) using Davis’ oxaziridine 14 (7.64 g, 25.6 mmol, 2.4 equiv). Evaporation in 
vacuo resulted in (S)-12 (3.02 g, 73%) as an orange powder. The enantiomeric excess was 76% 
as determined by chiral HPLC analysis. The powder was redissolved in 60 mL of boiling 
absolute ethanol and left untouched for 1 hour at room temperature. After 40 minutes fibers had 
formed, which were filtered off after an additional 20 minutes. This resulted in (S)-3’-
diallylaminoblebbistatin (S)-12 (1.03 g, 25%) as bright orange cotton-like fibers with an 
enantiomeric excess of >99%. mp 167 °C. Chiral HPLC: tR ((S)-12) = 27.1 min, 
tR ((R)-12) = 31.1 min (Daicel Chiralpak IA column, acetonitrile/water (45:55), 1.0 mL min
-1
, 
25 °C). [α]25D = −248 ± 2 (c = 0.11 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): 
δ = 2.19–2.27 (m, 2H), 2.30 (s, 3H), 3.87–3.95 (m, 1H), 3.94–4.07 (m, 5H), 3.12–5.24 (m, 4H), 
5.92 (ddt, J = 17.1, 10.2, 5.1 Hz, 2H), 6.47 (dd, J = 8.1, 2.0 Hz, 1H), 6.79 (s, 1H), 6.98 (dd, 
J = 8.1, 2.0 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.15 (t,  J = 8.1 Hz, 1H), 7.38 (dd, J = 8.1, 1.8 Hz, 
1H), 7.52 (d, J = 1.8 Hz, 1H), 7.94 (t, J = 2.0 Hz, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): 
δ = 20.7, 28.8, 47.9, 53.0, 73.5, 104.8, 107.4, 108.3, 116.4, 121.4, 126.2, 126.8, 129.4, 132.5, 
134.8, 137.0, 141.9, 148.9, 149.8, 165.7, 195.1. MS (ESI): m/z (%) = 387.5 ([M+H]
+
, 100). 
HRMS (ESI): calculated for C24H26N3O2 ([M+H]
+
) 388.2020; found 388.2035. MW = 387.47.
 
1
H NMR spectrum, 
13
C NMR spectrum and chiral HPLC chromatograms are provided in 
Figures S34–S35 and Figures S57–S58 in the Supporting Information. 
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1.2.6. (R)-1-(3-(diallyl-amino)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-
pyrrolo[2,3-b]quinolin-4 one ((R)-12) 
(R)-3’-diallylaminoblebbistatin (R)-12 was synthesized from the crude quinolone 9c (0.967 g, 
2.60 mmol, 1 equiv) using Davis’ oxaziridine 15 (1.86 g, 6.24 mmol, 2.4 equiv). Evaporation in 
vacuo resulted in (R)-3’-diallylaminoblebbistatin (R)-12 (0.686 g, 68%) as an orange powder. 
The enantiomeric excess was 74% as determined by chiral HPLC analysis. The powder was 
redissolved in 15 mL of boiling absolute ethanol and left untouched for 50 minutes at room 
temperature. After 30 minutes fibers had formed, which were filtered off after an additional 
20 minutes. This resulted in (R)-3’-diallylaminoblebbistatin (R)-12 (0.160 g, 16%) as bright 
orange cotton-like fibers with an enantiomeric excess of 98%. mp 167 °C. Chiral HPLC: 
tR ((R)-12) = 31.1 min, tR ((S)-12) = 27.7 min (Daicel Chiralpak IA column, acetonitrile/water 
(45:55), 1.0 mL min
-1
, 25 °C). [α]25D = +327 ± 3 (c = 0.18 in tetrahydrofuran). 
1
H NMR 
(400 MHz, DMSO-d6): δ = 2.19–2.27 (m, 2H), 2.30 (s, 3H), 3.87–3.95 (m, 1H), 3.94–4.07 (m, 
5H), 3.12–5.24 (m, 4H), 5.92 (ddt, J = 17.1, 10.2, 5.1 Hz, 2H), 6.47 (dd, J = 8.1, 2.0 Hz, 1H), 
6.79 (s, 1H), 6.98 (dd, J = 8.1, 2.0 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.15 (t,  J = 8.1 Hz, 1H), 
7.38 (dd, J = 8.1, 1.8 Hz, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.94 (t, J = 2.0 Hz, 1H). 
13
C NMR 
(100.6 MHz, DMSO-d6): δ = 20.7, 28.8, 47.9, 53.0, 73.5, 104.8, 107.4, 108.3, 116.4, 121.4, 
126.2, 126.8, 129.4, 132.5, 134.8, 137.0, 141.9, 148.9, 149.8, 165.7, 195.1. MS (ESI): m/z (%) = 
387.5 ([M+H]
+
, 100). HRMS (ESI): calculated for C24H26N3O2 ([M+H]
+
) 388.2020; found 
388.2023. MW = 387.47. Chiral HPLC chromatogram is provided in Figure S60 in the 
Supporting Information. 
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1.2.7. (S)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzonitrile ((S)-13) 
(S)-3’-cyanoblebbistatin (S)-13 was synthesized from quinolone 9d (1.51 g, 5.00 mmol, 
1 equiv) using Davis’ oxaziridine 14 (3.58 g, 12.0 mmol, 2.4 equiv). Evaporation in vacuo 
resulted in (S)-13 (1.54 g, 97%) as a yellow powder. The enantiomeric excess was 83% as 
determined by chiral HPLC analysis. mp 235 °C. Chiral HPLC: tR ((S)-13) = 7.68 min, 
tR ((R)-13) = 10.1 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 
25 °C). [α]25D = −248 ± 2 (c = 0.11 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): 
δ = 2.25–2.36 (m, 5H), 3.97–4.12 (m, 2H), 6.92 (s, 1H), 7.19 (d, J = 8.2 Hz, 1H), 7.42 (dd, 
J = 8.2, 2.0 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.59 (dt, J = 8.0, 1.3 Hz, 1H), 7.65 (t, J = 8.0 Hz, 
1H), 8.45 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 8.61 (t, J = 1.7 Hz, 1H). 
13
C NMR (100.6 MHz, 
DMSO-d6): δ = 20.7, 28.6, 47.8, 73.2, 112.1, 119.3, 121.6, 122.6, 124.2, 126.6, 126.9, 127.1, 
130.6, 133.6, 137.0, 141.7, 148.7, 165.9, 194.7. MS (ESI): m/z (%) = 317.6 ([M+H]
+
, 100). 
HRMS (ESI): calculated for C19H16N3O2 ([M+H]
+
) 318.1237; found 318.1247. MW = 317.35.
 
1
H NMR spectrum, 
13
C NMR spectrum and chiral HPLC chromatograms are provided in 
Figures S32–S33 and Figures S54–S55 in the Supporting Information. 
1.2.8. (R)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzonitrile ((R)-13) 
(R)-3’-cyanoblebbistatin (R)-13 was synthesized from quinolone 9d (1.51 g, 5.00 mmol, 
1 equiv) using Davis’ oxaziridine 15 (3.58 g, 12.0 mmol, 2.4 equiv). Evaporation in vacuo 
resulted in (R)-13 (1.50 g, 95%) as a yellow powder. The enantiomeric excess was 84% as 
determined by chiral HPLC analysis. mp 232 °C. Chiral HPLC: tR ((R)-13) = 9.88 min, 
tR ((S)-13) = 7.67 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 
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25 °C). [α]25D = +251 ± 2 (c = 0.14 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): 
δ = 2.25–2.36 (m, 5H), 3.97–4.12 (m, 2H), 6.92 (s, 1H), 7.19 (d, J = 8.2 Hz, 1H), 7.42 (dd, 
J = 8.2, 2.0 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.59 (dt, J = 8.0, 1.3 Hz, 1H), 7.65 (t, J = 8.0 Hz, 
1H), 8.45 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 8.61 (t, J = 1.7 Hz, 1H). 
13
C NMR (100.6 MHz, 
DMSO-d6): δ = 20.7, 28.6, 47.8, 73.2, 112.1, 119.3, 121.6, 122.6, 124.2, 126.6, 126.9, 127.1, 
130.6, 133.6, 137.0, 141.7, 148.7, 165.9, 194.7. MS (ESI): m/z (%) = 317.6 ([M+H]
+
, 100). 
HRMS (ESI): calculated for C19H16N3O2 ([M+H]
+
) 318.1237; found 318.1236. MW = 317.35. 
Chiral HPLC chromatogram is provided in Figure S56 in the Supporting Information. 
1.3. General procedure for the allyl deprotection of allyl phenyl ethers 
The allyl deprotection of allyl phenyl ethers (S)-11 and (R)-11 was adopted from a publication 
of Vutukuri et al.
33
 
In a flame-dried bulb of 250 mL containing 200 mL of dry methanol, allyl phenyl ether 
(4.21 mmol, 1 equiv) and 0.243 g of tetrakis(triphenylphosphine)palladium(0) (0.211 mmol, 
0.05 equiv) were brought together under a nitrogen atmosphere and stirred for 5 minutes at room 
temperature. Then, 3.49 g of K2CO3 (25.3 mmol, 6 equiv) was added and the reaction mixture 
was stirred for 1 hour at 50 °C. Afterwards, the mixture was concentrated to a volume of 25 mL, 
diluted with 400 mL of ethyl acetate, washed with saturated aqueous NH4Cl (2× 75 mL). Next, 
the organic layer was dried over magnesium sulfate and evaporated in vacuo. 
1.3.1. (S)-3a-hydroxy-1-(3-hydroxyphenyl)-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-2) 
(S)-3’-hydroxyblebbistatin (S)-2 was synthesized from (S)-3’-allyloxyblebbistatin (S)-11 
(1.47 g, 4.21 mmol, 1 equiv). Evaporation in vacuo afforded a bright red powder (1.53 g) which 
was dissolved in tetrahydrofuran and coated under reduced pressure onto 4.60 g of silica. 
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Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 80 g silica cartridge (2% sample loading; flow 
rate: 60 mL min
-1
; eluent: 2 CV of 15% ethyl acetate, followed by a gradient from 15% to 100% 
ethyl acetate over 15 CV and finally 2 CV of 100% ethyl acetate; detection wavelengths: 220 nm 
and 264 nm). This resulted in (S)-3’-hydroxyblebbistatin (S)-2 (1.03 g, 79%) as a bright orange 
powder. The enantiomeric excess was 99% as determined by chiral HPLC analysis. mp 179 °C. 
Rf = 0.40 (hexane/ethyl acetate, 2:3). Chiral HPLC: tR ((S)-2) = 3.87 min, tR ((R)-2) = 5.18 min 
(Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 25 °C). [α]25D = −332 ± 3 
(c = 0.11 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.20–2.27 (m, 2H), 2.31 (s, 
3H), 3.87–3.95 (m, 1H), 3.96–4.06 (m, 1H), 6.56 (dd, J = 8.1, 2.1 Hz, 1H), 6.81 (s, 1H), 7.12 (d, 
J = 8.1 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.35–7.41 (m, 2H), 7.53 (d, J = 1.6 Hz, 1H), 7.71 (t, 
J = 2.1 Hz, 1H), 9.50 (s, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.7, 48.0, 73.4, 
107.6, 110.8, 111.2, 121.4, 126.3, 126.8, 129.8, 132.7, 136.9, 142.1, 149.7, 158.0, 165.7, 195.1. 
MS (ESI): m/z (%) = 308.7 ([M+H]
+
, 100). HRMS (ESI): calculated for C18H17N2O3 ([M+H]
+
) 
309.1234; found 309.1233. MW = 308.33.
 1
H NMR spectrum, 
13
C NMR spectrum and chiral 
HPLC chromatograms are provided in Figures S36–S37 and Figures S60–S61 in the Supporting 
Information. X-ray data are provided in Figures S1–S2 in the Supporting Information. 
1.3.2. (R)-3a-hydroxy-1-(3-hydroxyphenyl)-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((R)-2) 
(R)-3’-hydroxyblebbistatin (R)-2 was synthesized from (R)-3’-allyloxyblebbistatin (R)-11 
(0.182 g, 0.521 mmol, 1 equiv). Evaporation in vacuo afforded an orange oil (0.200 g) which 
was dissolved in tetrahydrofuran and coated under reduced pressure onto 0.600 g of silica. 
Subsequently, purification was performed via automated flash chromatography with 
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hexane/ethyl acetate as eluent on a Reveleris® 12 g silica cartridge (2% sample loading; flow 
rate: 36 mL min
-1
; eluent: 2 CV of 15% ethyl acetate, followed by a gradient from 15% to 100% 
ethyl acetate over 15 CV and finally 2 CV of 100% ethyl acetate; detection wavelengths: 220 nm 
and 264 nm). This resulted in (R)-3’-hydroxyblebbistatin (R)-2 (0.120 g, 75%) as a bright orange 
powder. The enantiomeric excess was 98% as determined by chiral HPLC analysis. mp 202 °C. 
Rf = 0.40 (hexane/ethyl acetate, 2:3). Chiral HPLC: tR ((R)-2) = 5.11 min, tR ((S)-2) = 3.91 min 
(Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 25 °C). [α]25D = +320 ± 3 
(c = 0.12 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.20–2.27 (m, 2H), 2.31 (s, 
3H), 3.87–3.95 (m, 1H), 3.96–4.06 (m, 1H), 6.56 (dd, J = 8.1, 2.1 Hz, 1H), 6.81 (s, 1H), 7.12 (d, 
J = 8.1 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.35–7.41 (m, 2H), 7.53 (d, J = 1.6 Hz, 1H), 7.71 (t, 
J = 2.1 Hz, 1H), 9.50 (s, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.7, 48.0, 73.4, 
107.6, 110.8, 111.2, 121.4, 126.3, 126.8, 129.8, 132.7, 136.9, 142.1, 149.7, 158.0, 165.7, 195.1. 
MS (ESI): m/z (%) = 308.6 ([M+H]
+
, 100). HRMS (ESI): calculated for C18H17N2O3 ([M+H]
+
) 
309.1234; found 309.1239. MW = 308.33. Chiral HPLC chromatogram is provided in 
Figure S62 in the Supporting Information. X-ray data are provided in Figures S3–S4 in the 
Supporting Information. 
1.4. General procedure for the allyl deprotection of diallyl phenyl amines 
The allyl deprotection of diallyl phenyl amines (S)-12 and (R)-12 was based on a publication 
of Belardi and Micalizio.
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In a flame-dried bulb of 25 mL containing 20 mL of dry dichloromethane, 0.358 g of diallyl 
phenyl amine (0.924 mmol, 1 equiv), 0.865 g of N,N’-dimethylbarbituric acid (5.55 mmol, 
6 equiv) and 0.106 g of tetrakis(triphenylphosphine)palladium(0) (0.0924 mmol, 0.1 equiv) were 
brought together under a nitrogen atmosphere and stirred for 1 hour at reflux temperature. 
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Afterwards, the reaction mixture cooled to room temperature, diluted with 150 mL of ethyl 
acetate and washed with saturated aqueous NaHCO3 (2× 50 mL). The organic layer was dried 
over magnesium sulfate and evaporated in vacuo. 
1.4.1. (S)-1-(3-aminophenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-3) 
(S)-3’-aminoblebbistatin (S)-3 was synthesized from (S)-3’-diallylaminoblebbistatin (S)-12 
(0.358 g, 0.924 mmol, 1 equiv). Evaporation in vacuo afforded a brown oil (0.496 g) which was 
taken up in tetrahydrofuran and coated under reduced pressure onto 1.49 g of silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 40 g silica cartridge (1% sample loading; flow 
rate: 40 mL min
-1
; eluent: 2 CV of 20% ethyl acetate, followed by a gradient from 20% to 100% 
ethyl acetate over 20 CV and finally 2 CV of 100% ethyl acetate; detection wavelengths: 220 nm 
and 264 nm). This resulted in (S)-3’-aminoblebbistatin (S)-3 (0.215 g, 76%) as a dark yellow-
orange powder. The enantiomeric excess was >99% as determined by chiral HPLC analysis. 
mp 207 °C. Rf = 0.33 (hexane/ethyl acetate, 1:4). Chiral HPLC: tR ((S)-3) = 4.41 min, 
tR ((R)-3) = 6.35 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 
25 °C). [α]25D = −383 ± 3 (c = 0.10 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): 
δ = 2.18–2.26 (m, 2H), 2.30 (s, 3H), 3.82–3.91 (m, 1H), 3.93–4.05 (m, 1H), 5.14 (br. s, 2H), 6.37 
(dd, J = 8.0, 1.8 Hz, 1H), 6.78 (s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 7.17 
(dd, J = 8.0, 1.8 Hz, 1H), 7.34 (t, J = 1.8 Hz, 1H), 7.37 (dd, J = 8.1, 1.9 Hz, 1H), 7.51 (d, 
J = 1.9 Hz, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.3, 48.0, 73.4, 106.1, 108.2, 
110.3, 121.4, 126.3, 126.7, 129.4, 132.4, 136.9, 141.7, 149.4, 150.0, 165.6, 195.2. MS (ESI): 
m/z (%) = 307.7 ([M+H]
+
, 100). HRMS (ESI): calculated for C18H18N3O2 ([M+H]
+
) 308.1394; 
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found 308.1387. MW = 307.35.
 1
H NMR spectrum, 
13
C NMR spectrum and chiral HPLC 
chromatograms are provided in Figures S38–S39 and Figures S63–S64 in the Supporting 
Information. 
1.4.2. (R)-1-(3-aminophenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((R)-3) 
(R)-3’-aminoblebbistatin (R)-3 was synthesized from (R)-3’-diallylaminoblebbistatin (R)-12 
(0.0530 g, 0.137 mmol, 1 equiv). Evaporation in vacuo afforded a brown oil (0.0731 g) which 
was taken up in tetrahydrofuran and coated under reduced pressure onto 0.219 g of silica. 
Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 12 g silica cartridge (1% sample loading; flow 
rate: 36 mL min
-1
; eluent: 2 CV of 20% ethyl acetate, followed by a gradient from 20% to 100% 
ethyl acetate over 20 CV and finally 2 CV of 100% ethyl acetate; detection wavelengths: 220 nm 
and 264 nm). This resulted in (R)-3’-aminoblebbistatin (R)-3 (0.0301 g, 72%) as a dark yellow-
orange powder. The enantiomeric excess was 95% as determined by chiral HPLC analysis. 
mp 174 °C. Rf = 0.33 (hexane/ethyl acetate, 1:4). Chiral HPLC: tR ((R)-3) = 6.35 min, tR ((S)-
3) = 4.44 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min
-1
, 25 °C). 
[α]25D = +358 ± 4 (c = 0.11 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.18–2.26 
(m, 2H), 2.30 (s, 3H), 3.82–3.91 (m, 1H), 3.93–4.05 (m, 1H), 5.14 (br. s, 2H), 6.37 (dd, J = 8.0, 
1.8 Hz, 1H), 6.78 (s, 1H), 7.04 (t, J = 8.0 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 7.17 (dd, J = 8.0, 
1.8 Hz, 1H), 7.34 (t, J = 1.8 Hz, 1H), 7.37 (dd, J = 8.1, 1.9 Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.3, 48.0, 73.4, 106.1, 108.2, 110.3, 121.4, 126.3, 
126.7, 129.4, 132.4, 136.9, 141.7, 149.4, 150.0, 165.6, 195.2. MS (ESI): m/z (%) = 307.7 
([M+H]
+
, 100). HRMS (ESI): calculated for C18H18N3O2 ([M+H]
+
) 308.1394; found 308.1403. 
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MW = 307.35. Chiral HPLC chromatogram is provided in Figure S65 in the Supporting 
Information. 
1.5. General procedure for the selective hydrolysis of nitriles to amides 
The selective hydrolysis of nitriles (S)-13 and (R)-13 to amides (S)-16 and (R)-16 was 
performed via an adopted procedure from Fowler et al.
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In a flame-dried bulb of 250 mL containing 150 mL of dry dichloromethane, nitrile 
(3.18 mmol, 1 equiv) and 1.31 mL of N,N-diethylhydroxylamine (12.7 mmol, 4 equiv) were 
brought together under a nitrogen atmosphere and the reaction mixture was stirred at reflux 
temperature for 24 hours. Next, a second portion of N,N-diethylhydroxylamine (1.31 mL, 
12.7 mmol, 4 equiv) was added and the reaction mixture was refluxed for another 24 hours. 
During the reaction, the product had precipitated. After cooling to room temperature, the solids 
were filtered off on a sintered glass Büchner funnel and rinsed with ice-cold dichloromethane 
until the filtrate turned colorless. The residue was dried under reduced pressure. 
1.5.1. (S)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzamide ((S)-16) 
(S)-3’-carbamoylblebbistatin (S)-16 was synthesized from (S)-3’-cyanoblebbistatin (S)-13 
(1.01 g, 3.18 mmol, 1 equiv). Drying of the residue under reduced pressure afforded (S)-16 
(0.969 g, 91%) as an ochreous powder. The enantiomeric excess was 86% as determined by 
chiral HPLC analysis. Portions of 190 mg of the powder were redissolved in 80 mL of boiling 
absolute ethanol. The cooling solution was left untouched for 24 hours at room temperature, 
during which time yellow fibers had formed. In one case, evaporation in vacuo of the mother 
liquor resulted in (S)-3’-carbamoylblebbistatin (S)-16 (0.152 g, 73%) as a yellow powder with an 
enantiomeric excess of 98%. In one other case, the crop afforded (S)-3’-carbamoylblebbistatin 
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(S)-16 (0.0422 g, 20%) as bright yellow fibers with an enantiomeric excess of 98%. The three 
other recrystallizations resulted in scalemic mixtures in both the crops and the mother liquors. In 
those cases the crop and the mother liquor were recombined and the recrystallization protocol 
was repeated. mp 267 °C. Chiral HPLC: tR ((S)-16) = 20.9 min, tR ((R)-16) = 17.6 min (Daicel 
Chiralpak IA column, hexane/dichloromethane/absolute ethanol (10:90:3), 0.5 mL min
-1
, 35 °C). 
[α]25D = −288 ± 5 (c = 0.07 in tetrahydrofuran). 
1
H NMR (400 MHz, DMSO-d6): δ = 2.25–2.36 
(m, 5H), 3.97–4.06 (m, 1H), 4.05–4.16 (m, 1H), 6.87 (s, 1H), 7.13 (d, J = 8.1 Hz, 1H), 7.39 (dd, 
J = 8.1, 1.7 Hz, 1H), 7.42 (br. s, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.64 (d, 
J = 7.9 Hz, 1H), 8.02 (br. s, 1H), 8.24 (br. s, 1H), 8.52 (dd, J = 7.9, 1.6 Hz, 1H). 
13
C NMR 
(100.6 MHz, DMSO-d6): δ = 20.7, 28.8, 48.0, 73.3, 118.9, 121.5, 122.9, 123.2, 126.4, 126.8, 
129.0, 132.9, 135.4, 136.9, 141.0, 149.4, 165.8, 168.2, 195.0. MS (ESI): m/z (%) = 335.6 
([M+H]
+
, 100). HRMS (ESI): calculated for C19H18N3O3 ([M+H]
+
) 336.1343; found 336.1346. 
MW = 335.36.
 1
H NMR spectrum, 
13
C NMR spectrum and chiral HPLC chromatograms are 
provided in Figures S40–S41 and Figures S66–S67 in the Supporting Information. 
1.5.2. (R)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzamide ((R)-16) 
(R)-3’-carbamoylblebbistatin (R)-16 was synthesized from (R)-3’-cyanoblebbistatin (R)-13 
(1.01 g, 3.18 mmol, 1 equiv). Drying under reduced pressure afforded (R)-16 (0.955 g, 90%) as 
an ochreous powder. The enantiomeric excess was 86% as determined by chiral HPLC analysis. 
Portions of 190 mg of the powder were redissolved in 80 mL of boiling absolute ethanol. The 
solutions were left untouched for 24 hours at room temperature, during which time yellow fibers 
had formed. In one case, evaporation in vacuo of the mother liquor resulted in (R)-3’-
carbamoylblebbistatin (R)-16 (0.103 g, 49%) as a yellow powder with an enantiomeric excess of 
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97%. The four other recrystallizations resulted in scalemic mixtures in both the crops and the 
mother liquors. In those cases the crop and the mother liquor were recombined and the 
crystallization protocol was repeated. mp 267 °C. Chiral HPLC: tR ((R)-16) = 17.3 min, 
tR ((S)-16) = 21.4 min (Daicel Chiralpak IA column, hexane/dichloromethane/absolute ethanol 
(10:90:3), 0.5 mL min
-1
, 35 °C). [α]25D = +269 ± 8 (c = 0.07 in tetrahydrofuran). 
1
H NMR 
(400 MHz, DMSO-d6): δ = 2.25–2.36 (m, 5H), 3.97–4.06 (m, 1H), 4.05–4.16 (m, 1H), 6.87 (s, 
1H), 7.13 (d, J = 8.1 Hz, 1H), 7.39 (dd, J = 8.1, 1.7 Hz, 1H), 7.42 (br. s, 1H), 7.51 (t, J = 7.9 Hz, 
1H), 7.55 (d, J = 1.7 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 8.02 (br. s, 1H), 8.24 (br. s, 1H), 8.52 (dd, 
J = 7.9, 1.6 Hz, 1H). 
13
C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.8, 48.0, 73.3, 118.9, 121.5, 
122.9, 123.2, 126.4, 126.8, 129.0, 132.9, 135.4, 136.9, 141.0, 149.4, 165.8, 168.2, 195.0. MS 
(ESI): m/z (%) = 335.6 ([M+H]
+
, 100). HRMS (ESI): calculated for C19H18N3O3 ([M+H]
+
) 
336.1343; found 336.1340. MW = 335.36. Chiral HPLC chromatogram is provided in 
Figure S68 in the Supporting Information. 
1.6. General procedure for the hydrolysis of amides to carboxylic acids 
A bulb of 10 mL was loaded with 4.6 mL of demineralized water, 0.74 mL of concentrated 
H2SO4 (13.6 mmol, 30 equiv) and amide (0.457 mmol, 1 equiv), after which the reaction mixture 
was stirred at 70 °C for 14 hours. The resulting black slurry was filtered off over celite and the 
filter cake was rinsed with demineralized water until the filtrate turned colorless. Afterwards, the 
pH of the yellow filtrate was adjusted to 4–5 with 3 M aqueous NaOH and the water was 
lyophilized during 21 hours (0.31 mbar, 21 °C). This resulted in a light yellow powder 
containing the product together with salts such as Na2SO4. Isolation of the product from this 
mixture was conducted by stirring the powder in 90 mL of absolute ethanol for 30 minutes. Next, 
the solids were filtered off on a sintered glass Büchner funnel. The filter cake was rinsed with 
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absolute ethanol until the filtrate turned colorless, upon which the filtrate was evaporated in 
vacuo. 
To overcome the separation difficulties associated with chiral HPLC analysis of carboxylic 
acids (S)-17 and (R)-17, an analytical sample was converted into the corresponding methyl esters 
by means of diazomethane. A vial, equipped with a stirring bar, was loaded with a pinch of 
carboxylic acid, 0.3 mL of methanol and 20 drops of freshly prepared diazomethane. For the 
preparation of diazomethane, see the Supporting Information. CAUTION! Due to the dangers 
associated with diazomethane handling, sharp edged glassware was avoided, and 
diazomethane was added using a Pasteur pipette which was fire polished prior to use. 
When dealing with diazomethane, the experimenter should first thoroughly study the 
literature on the properties and safe handling of this hazardous reagent.
36,37
 The reaction 
mixture was stirred at room temperature for 45 minutes, during which the carboxylic acid 
functionality was almost completely converted into the corresponding methyl ester without 
affecting the alcohol moiety (
1
H NMR spectrum and LC-MS chromatogram are provided in 
Figures S44-S47 in the Supporting Information as proofs of conversion). Excess diazomethane 
and the solvent were evaporated under a flow of nitrogen gas. The yellow residue was 
redissolved in 1 mL of acetonitrile and analyzed as such. 
1.6.1. (S)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzoic acid ((S)-17) 
(S)-3’-carboxyblebbistatin (S)-17 was synthesized from (S)-3’-carbamoylblebbistatin (S)-16 
(0.153 g, 0.457 mmol, 1 equiv). Evaporation in vacuo of the filtrate afforded a yellow powder 
(0.108 g) which was dissolved in 2.5 mL of absolute ethanol and further purified via preparative 
TLC with dichloromethane/methanol (9:1) as eluent. This resulted in (S)-3’-carboxyblebbistatin 
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(S)-17 (0.0332 g, 22%) as a bright orange powder. The enantiomeric excess of the corresponding 
(S)-methyl ester (see general procedure above) was 96% as determined by chiral HPLC analysis. 
mp 250 °C. Rf = 0.14 (dichloromethane/methanol, 9:1). Chiral HPLC (S)-methyl ester: tR ((S)-
methyl ester) = 61.6 min, tR ((R)-methyl ester) = 73.6 min (Daicel Chiralpak IA column, 
acetonitrile/water (30:70), 1.0 mL min
-1
, 25 °C). [α]25D = −217 ± 3 (c = 0.11 in absolute ethanol). 
1
H NMR (400 MHz, 0.18 M NaHCO3 in D2O): δ = 2.22 (s, 3H), 2.30–2.38 (m, 2H), 3.91–4.00 
(m, 1H), 4.05–4.16 (m, 1H), 6.96 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.46 (t, 
J = 7.9 Hz, 1H), 7.55 (br. s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.94 (br. s, 
1H). 
13
C NMR (100.6 MHz, 0.18 M NaHCO3 in D2O): δ = 19.6, 28.2, 49.4, 73.8, 120.1, 123.1, 
124.8, 125.7, 126.5, 127.2, 129.2, 133.9, 137.5, 138.3, 138.8, 148.8, 160.4, 166.0, 174.8, 196.5. 
MS (ESI): m/z (%) = 336.6 ([M+H]
+
, 100). HRMS (ESI): calculated for C19H17N2O4 ([M+H]
+
) 
337.1183; found 337.1181. MW = 336.35.
 1
H NMR spectrum and 
13
C NMR spectrum of (S)-17 
are provided in Figures S42–S43 in the Supporting Information. Chiral HPLC chromatograms of 
(S)-methyl ester are provided in Figures S69–S70 in the Supporting Information. 
1.6.2. (R)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)benzoic acid ((R)-17) 
(R)-3’-carboxyblebbistatin (R)-17 was synthesized from (R)-3’-carbamoylblebbistatin (R)-16 
(0.0500 g, 0.149 mmol, 1 equiv). Evaporation in vacuo of the filtrate afforded (R)-3’-
carboxyblebbistatin (R)-17 (0.0378 g, 75%) as a bright yellow powder. The enantiomeric excess 
of (R)-methyl ester (see general procedure above) was 91% as determined by chiral HPLC 
analysis. mp 250 °C. Chiral HPLC (R)-methyl ester: tR ((R)-methyl ester) = 73.3 min, 
tR ((S)-methyl ester) = 62.7 min (Daicel Chiralpak IA column, acetonitrile/water (30:70), 
1.0 mL min
-1
, 25 °C). [α]25D = +172 ± 5 (c = 0.11 in absolute ethanol). 
1
H NMR (400 MHz, 
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0.24 M NaHCO3 in D2O): δ = 2.22 (s, 3H), 2.30–2.38 (m, 2H), 3.91–4.00 (m, 1H), 4.05–4.16 (m, 
1H), 6.96 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.55 (br. s, 1H), 
7.68 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.94 (br. s, 1H). 
13
C NMR (100.6 MHz, 
0.24 M NaHCO3 in D2O): δ = 19.6, 28.2, 49.4, 73.8, 120.1, 123.1, 124.8, 125.7, 126.5, 127.2, 
129.2, 133.9, 137.5, 138.3, 138.8, 148.8, 160.4, 166.0, 174.8, 196.5. MS (ESI): m/z (%) = 336.6 
([M+H]
+
, 100). HRMS (ESI): calculated for C19H17N2O4 ([M+H]
+
) 337.1183; found 337.1188. 
MW = 336.35. Chiral HPLC chromatogram of (R)-methyl ester is provided in Figure S71 in the 
Supporting Information. 
2. ATPase assay 
2.1. Preparation of F-actin filaments stock solution 
Pre-formed rabbit skeletal muscle F-actin filaments (cat. # AKF99) were purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 2.4 mL of Milli-Q 
water and gently mixed to a concentration of 0.4 mg mL
-1
. To allow filaments to dissociate from 
each other, this solution was incubated at room temperature for 10 minutes. Then, the filaments 
were aliquoted into 100 µL samples, snap frozen in liquid nitrogen and stored at −80 °C. 
Compounds (S)-1–3,13,16,17 were evaluated with the same batch of pre-formed rabbit skeletal 
muscle F-actin filaments. 
2.2. Preparation of myosin stock solution 
Full-length rabbit skeletal muscle myosin II protein (cat. # MY02) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 100 µL of Milli-Q 
water containing 1 mM DTT and incubated on ice for 5 minutes to completely solubilize it to a 
concentration of 10 mg mL
-1
. Care should be taken not to vortex the solution, in order to avoid 
protein denaturation caused by shear stress. Then, the myosin solution was further aliquoted into 
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10 µL samples, snap frozen in liquid nitrogen and stored at −80 °C. Compounds (S)-1–
3,13,16,17 were evaluated with the same batch of full-length rabbit skeletal muscle myosin II 
protein 
2.3. Preparation of ATP stock solution 
Adenosine 5’-triphosphate disodium salt (ATP, cat. # BSA04) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The ATP was reconstituted to 100 mM with 1 mL 
of ice-cold 100 mM Tris-HCl pH 7.5 and then aliquoted into 10 µL samples, snap frozen in 
liquid nitrogen and stored at −20 °C. Compounds (S)-1–3,13,16,17 were evaluated with the same 
batch of adenosine 5’-triphosphate disodium salt. 
2.4. ATPase assay 
Screening for inhibitors of rabbit skeletal muscle myosin II ATPase was performed in an 
ATPase end-point assay adapted from the method by Kodama et al.
38
 Incubation times and 
amounts of F-actin and myosin are based on a publication of Cheung et al.
39
 As the linear range 
for inorganic phosphate detection of the assay extends from approximately 0.1 nmol to 1.6 nmol 
of inorganic phosphate, a total amount of 1.6 nmol ATP was used.
40
  
Prior to each assay, aliquoted samples of F-actin, myosin and ATP were defrosted rapidly in a 
37 °C water bath and further dilutions were made: myosin was diluted to 33 µg mL
-1
 with ice-
cold reaction buffer (15 mM Tris-HCl pH 7.5, 25 mM KCl, 10 mM MgCl2, 0.1 mM EGTA) and 
stored on ice, ATP was diluted to 0.04 mM with ice-cold 15 mM Tris-HCl pH 7.5 and stored on 
ice, F-actin was diluted to 133 µg mL
-1
 with reaction buffer and stored at room temperature. 
Chemical compounds dissolved in DMSO (1 µL) were transferred into each well of a 96-well 
plate. Then, 15 µL of reaction buffer, 15 µL of 133 µg mL
-1
 F-actin and 15 µL of 33 µg mL
-1
 
myosin were subsequently distributed in each well using a multichannel pipette. Afterwards, the 
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ATP hydrolysis reaction was initiated by adding 15 µL of 0.04 mM ATP per well using a 
multichannel pipette and was then incubated for 1 hour at 37 °C. To measure the amount of 
inorganic phosphate (Pi) generated during the enzymatic hydrolysis of ATP, 139 µL of 
development solution (CytoPhos™ reagent, cat. # BK054 from Cytoskeleton) was added to each 
well using a multichannel pipette. After 20 minutes, the absorbance at 650 nm was measured in 
each assay well using a SpectraMax
®
 Paradigm
®
 Multi-Mode Microplate Reader. On each assay 
plate, two concentrations of (S)-1 (2.25 µM and 32.5 µM) were included as a positive control, 
and the resulting amount of inhibition was comparable over the different assay plates. All 
screenings were carried out twice (N = 2). 
2.5. IC50 determination 
Dose-response curves were generated using the SoftMax Pro v6.1 software. Data points 
representing the means ± s.d. of at least three samples, were plotted on semi-log axes and a 
4-parameter logistic curve, based on the following equation, was fitted to the means. 
y = A + 
B - A
1 + (
x
C
)
D
 
Here, y represents the ATPase activity of rabbit skeletal muscle myosin II (%) and x 
corresponds to the compound concentration (µM). A is the ATPase activity corresponding to the 
asymptote at high compound concentrations (%), B is the ATPase activity corresponding to the 
asymptote at low compound concentrations (%), C represents the compound concentration 
corresponding to the midpoint between A and B (µM) (i.e. IC50 value), and D describes how 
rapidly the curve makes its transition from the asymptotes in the center of the curve. 
3. Determination of aqueous solubility 
The aqueous solubility was determined by Eurofins Panlabs. 
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Compounds were added to a PBS pH 7.4 buffer as a 10 mM dimethyl sulfoxide (DMSO) 
solution and were incubated at room temperature while agitating the suspension. DMSO and 
compound concentrations were 2% (v/v) and 200 µM, respectively. After 24 hours, the 
suspension was centrifuged and filtered through a 0.2 µM filter membrane. Compound 
concentrations in the buffer sample were determined by HPLC. Absorption spectra (230 nm) 
were recorded and the concentration of the dissolved compound was determined by comparing 
the peak area of the principal peak in the buffer sample with the peak area of the corresponding 
peak in a calibration standard (200 µM) containing organic solvent (methanol/water (60:40)). 
The experiments were performed in duplicate. 
4. Cell culture 
The MCF-7/6 human breast carcinoma cell line was kindly provided by Dr. H. Rochefort 
(Unité d’Endocrinologie Cellulaire et Moléculaire, Montpellier, France). These cells were 
originally isolated from a pleural effusion of a breast adenocarcinoma.
41
 Cells were cultured in a 
DMEM/Ham’s F-12 (1:1) medium supplemented with 100 IU mL-1 penicillin (Gibco, 
Merelbeke, Belgium), 100 µg mL
-1
 streptomycin (Gibco, Merelbeke, Belgium) and 10% fetal 
bovine serum at 37 °C in a saturated atmosphere with 10% CO2. Tests for mycoplasma 
contamination are conducted monthly. 
5. Microscopic imaging of fluorescence 
MCF-7/6 human breast carcinoma cells (500 µL) were seeded at a density of 50000 cells/well 
in a 24-well plate. 24 h after seeding, cells were treated with 500 µL of different concentrations 
of test compounds or with DMSO as a solvent control (in threefold, final concentrations were 
5 µM or 50 µM, 0.1% DMSO). After 24 h of incubation, bright field images and fluorescence 
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images (488 nm excitation, GFP) were acquired on a Zeiss Axiovert 200M fluorescence 
microscope using a 20× objective. 
6. Fluorescence measurements 
Fluorescence measurements were performed using an Edinburgh Instruments F900 
Fluorescence Spectrometer equipped with a 450 W Xenon Lamp. Compounds were dissolved in 
methanol and further diluted with phosphate buffered saline (PBS) to obtain a final concentration 
of 20 µM. The amount of methanol was maintained at a constant concentration of 2.67% (v/v) in 
all samples. For all compounds, emission spectra were recorded after excitation at a wavelength 
of 365 nm and 488 nm (excitation bandwidth = 5 nm, emission bandwidth = 1 nm, dwell time = 
0.5 sec). A different sample was used for each wavelength. All compound emission spectra were 
corrected for the Raman lines of the solvent mixture by subtracting the emission spectrum of the 
solvent blank. 
 
SUPPORTING INFORMATION 
Synthetic protocols and compound characterization of compounds 4b, 4c, S5, 6a–d, 10, 7, 8a–d 
and 9a–d; X-ray crystallographic data of (S)-2 and (R)-2; 1H NMR spectra and 13C NMR spectra; 
chiral HPLC chromatograms; additional data relating to ATPase assay and microscopic imaging 
of fluorescence.  
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